Rare hereditary hemochromatosis

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:220489
Who is this for?
Show terms as
1Active trials24Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Rare hereditary hemochromatosis (Orphanet code 220489) encompasses the less common genetic forms of hereditary hemochromatosis beyond the classic HFE-related (type 1) form. These rare subtypes include juvenile hemochromatosis (type 2A caused by HJV/hemojuvelin mutations and type 2B caused by HAMP/hepcidin mutations), transferrin receptor 2-related hemochromatosis (type 3, caused by TFR2 mutations), and ferroportin disease (type 4, caused by SLC40A1 mutations). All forms are characterized by excessive iron absorption from the diet, leading to progressive iron overload in multiple organ systems. The liver, heart, pancreas, endocrine glands, joints, and skin are primarily affected. Clinical features vary by subtype but commonly include liver disease (hepatomegaly, fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma), cardiomyopathy, diabetes mellitus, hypogonadotropic hypogonadism, arthropathy, skin hyperpigmentation (bronze discoloration), and fatigue. Juvenile forms (type 2) tend to present earlier in life, often before age 30, with more severe cardiac and endocrine involvement, whereas type 3 resembles classic hemochromatosis in its clinical course. Ferroportin disease (type 4) has a distinct pathophysiology and may present with predominant macrophage iron loading and variable tolerance to phlebotomy. Diagnosis involves elevated serum ferritin and transferrin saturation, confirmed by genetic testing. Treatment primarily consists of therapeutic phlebotomy (regular blood removal) to reduce iron stores and prevent organ damage. In patients who cannot tolerate phlebotomy, iron chelation therapy may be used. Early diagnosis and treatment can prevent irreversible organ damage and significantly improve prognosis. Dietary modifications, including avoidance of iron supplements and limiting alcohol consumption, are also recommended as supportive measures.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Variable

Can begin at different ages, from infancy through adulthood

Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Oct 2023Fully Automated High-Throughput Quantitative MRI of the Liver

University of Wisconsin, Madison

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Rare hereditary hemochromatosis.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Other1 trial
Fully Automated High-Throughput Quantitative MRI of the Liver
Actively Recruiting
PI: Scott Reeder, MD, PhD (University of Wisconsin, Madison) · Sites: Madison, Wisconsin · Age: 799 yrs

Specialists

24 foundView all specialists →
AM
Ariel Koren, MD
Specialist
PI on 10 active trials1 Rare hereditary hemochromatosis publication
JP
John C Wood, MD, PhD
Specialist
PI on 2 active trials
MR
Marc RUIVARD
Specialist
PI on 2 active trials2 Rare hereditary hemochromatosis publications
OG
Orly Goitein
Specialist
PI on 1 active trial
AK
Andrea Kew
Specialist
PI on 1 active trial
JR
Jean-Michel Reymann
Specialist
PI on 1 active trial
PA
Prof. Mohsen S El Alfy
Specialist
PI on 1 active trial
PB
Pierre Brissot
Specialist
PI on 1 active trial
RC
Robert Christensen
Specialist
PI on 1 active trial
SP
Silverio Perrotta
Specialist
PI on 1 active trial
GT
Galina f Tereshchenko
Specialist
PI on 1 active trial
SK
Supreet Kaur
Specialist
PI on 1 active trial
PN
Pierre NAHON
Specialist
PI on 1 active trial
JJ
Jianmin Jianmin
Specialist
PI on 1 active trial
JF
Jonathan Fish
Specialist
PI on 1 active trial
JL
Jianmin Luo
Specialist
PI on 1 active trial
FK
Frank Korosec
Specialist
PI on 1 active trial
SR
Scott Reeder
MADISON, WI
Specialist
PI on 2 active trials
MY
Mohamed Yassin
PITTSBURGH, PA
Specialist
PI on 3 active trials
EV
Elliot Vichinsky
OAKLAND, CA
Specialist
PI on 1 active trial
GH
Ghoti Hossam
Specialist
PI on 2 active trials
BH
Balthasar L. Hug
Specialist
PI on 1 active trial
FR
Fariba Mansoori, Resident
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Rare hereditary hemochromatosis.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Rare hereditary hemochromatosisForum →

No community posts yet. Be the first to share your experience with Rare hereditary hemochromatosis.

Start the conversation →

Latest news about Rare hereditary hemochromatosis

Disease timeline:

New recruiting trial: Fully Automated High-Throughput Quantitative MRI of the Liver

A new clinical trial is recruiting patients for Rare hereditary hemochromatosis

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Rare hereditary hemochromatosis

What is Rare hereditary hemochromatosis?

Rare hereditary hemochromatosis (Orphanet code 220489) encompasses the less common genetic forms of hereditary hemochromatosis beyond the classic HFE-related (type 1) form. These rare subtypes include juvenile hemochromatosis (type 2A caused by HJV/hemojuvelin mutations and type 2B caused by HAMP/hepcidin mutations), transferrin receptor 2-related hemochromatosis (type 3, caused by TFR2 mutations), and ferroportin disease (type 4, caused by SLC40A1 mutations). All forms are characterized by excessive iron absorption from the diet, leading to progressive iron overload in multiple organ systems.

Are there clinical trials for Rare hereditary hemochromatosis?

Yes — 1 recruiting clinical trial is currently listed for Rare hereditary hemochromatosis on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Rare hereditary hemochromatosis?

24 specialists and care centers treating Rare hereditary hemochromatosis are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.